Acute prefrontal rTMS increases striatal dopamine to a similar degree as D-amphetamine.
Prefrontal repetitive transcranial magnetic stimulation (rTMS) has been shown to increase striatal dopaminergic activity. Here we investigated dopaminergic neurotransmission using single photon emission computed tomography (SPECT) and [(123)I]IBZM to indirectly assess the change in endogenous striatal dopamine concentration upon rTMS as compared with d-amphetamine challenge. SPECT imaging was performed twice each in five patients during rTMS, and in two patients who received 0.3 mg/kg D-amphetamine. Administration of rTMS led to a mean relative decrease in striatal IBZM binding by 9.6+/-6.2%, and d-amphetamine challenge (n=4) induced a mean relative reduction by 8+/-2.95% (difference not statistically significant). Acute rTMS challenge showed similar striatal dopaminergic effects to those associated with the administration of d-amphetamine, a substance known to increase synaptic dopamine.
Pogarell
Oliver
O
Department of Psychiatry, Ludwig-Maximilians-University of Munich, Munich, Germany.
Koch
Walter
W
Pöpperl
Gabriele
G
Tatsch
Klaus
K
Jakob
Franziska
F
Mulert
Christoph
C
Grossheinrich
Nicola
N
Rupprecht
Rainer
R
Möller
Hans-Jürgen
HJ
Hegerl
Ulrich
U
Padberg
Frank
F
D001549:Benzamides; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D003342:Corpus Striatum / Q000378:metabolism*; D003865:Major Depressive Disorder / Q000628:therapy*; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D017397:Prefrontal Cortex / Q000378:metabolism*; D011759:Pyrrolidines; D015899:Tomography, Emission-Computed, Single-Photon; D050781:Transcranial Magnetic Stimulation / Q000379:methods*
D001549:Benzamides; D000697:Central Nervous System Stimulants; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D003913:Dextroamphetamine